Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays

od Morice, Pierre-Marie, Coquan, Elodie, Weiswald, Louis-Bastien, Lambert, Bernard, Vaur, Dominique, Poulain, Laurent
Izdano u Br J Cancer (2021)

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

od Johnson, Alison C., Matias, Margarida, Boyle, Helen, Escudier, Bernard, Molinier, Alicia, Laguerre, Brigitte, Helissey, Carole, Brachet, Pierre-Emmanuel, Dugué, Audrey Emmanuelle, Mourey, Loic, Coquan, Elodie, Joly, Florence
Izdano u BMC Cancer (2017)

Predicting tumor response and outcome of second-look surgery with (18)F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in sta...

od Aide, Nicolas, Fauchille, Pauline, Coquan, Elodie, Ferron, Gwenael, Combe, Pierre, Meunier, Jérome, Alexandre, Jerôme, Berton, Dominique, Leary, Alexandra, De Rauglaudre, Gaétan, Bonichon, Nathalie, Pujade Lauraine, Eric, Joly, Florence
Izdano u Eur J Nucl Med Mol Imaging (2020)

Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

od Lange, Marie, Laviec, Heidi, Castel, Hélène, Heutte, Natacha, Leconte, Alexandra, Léger, Isabelle, Giffard, Bénédicte, Capel, Aurélie, Dubois, Martine, Clarisse, Bénédicte, Coquan, Elodie, Di Fiore, Frédéric, Gouérant, Sophie, Bartélémy, Philippe, Pierard, Laure, Fizazi, Karim, Joly, Florence
Izdano u BMC Cancer (2017)

Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

od Lange, Marie, Laviec, Heidi, Castel, Hélène, Heutte, Natacha, Leconte, Alexandra, Léger, Isabelle, Giffard, Bénédicte, Capel, Aurélie, Dubois, Martine, Clarisse, Bénédicte, Coquan, Elodie, Di Fiore, Frédéric, Gouérant, Sophie, Bartélémy, Philippe, Pierard, Laure, Fizazi, Karim, Joly, Florence
Izdano u BMC Cancer (2018)

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol

od Lesueur, Paul, Lequesne, Justine, Grellard, Jean-Michel, Dugué, Audrey, Coquan, Elodie, Brachet, Pierre-Emmanuel, Geffrelot, Julien, Kao, William, Emery, Evelyne, Berro, David Hassanein, Castera, Laurent, Goardon, Nicolas, Lacroix, Joëlle, Lange, Marie, Capel, Aurélie, Leconte, Alexandra, Andre, Benoit, Léger, Angélique, Lelaidier, Anaïs, Clarisse, Bénédicte, Stefan, Dinu
Izdano u BMC Cancer (2019)